The most-read coverage of the latest updates in acute myeloid leukemia (AML) for 2025 focused on the evolution of targeted ...
New developments in the complex and rapidly changing world of acute myeloid leukemia (AML) promise to improve health outcomes for people with the disease. They include: Advances in diagnostics ...
Midostaurin was granted a priority review for a new drug application by the FDA to treat a subset of patients with acute myeloid leukemia. Midostaurin (PKC412) was granted a priority review to a new ...
Relapsed acute myeloid leukemia (AML) is when cancer returns after a period of remission. Refractory AML means cancer has not responded to multiple rounds of treatment. Both can affect your treatment ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback